New Sinclair Pharma boss invests £822,000

A round-up of the biggest director deals today so far.

Sinclair Pharma's new chief executive and two non-executive directors all increased their shareholdings after the specialist pharma company's recent fundraising.

Sinclair raised £18.2m - £16m after expenses - at 32p a share to finance the purchase of Flammazine and Flammacerium, which are creams to prevent infections in burns, from Solvay. Sinclair paid €17.5m to Solvay for the two products, which generate annual revenues of more than £9m.

Try 6 free issues of MoneyWeek today

Get unparalleled financial insight, analysis and expert opinion you can profit from.

Start your trial
https://cdn.mos.cms.futurecdn.net/flexiimages/mw70aro6gl1676370748.jpg

Sign up for MoneyWeek’s free twice-daily newsletter.

Join more than 165,000 subscribers and keep yourself informed with latest financial news, insights and expert analysis to help you understand what really matters when it comes to your finances.

Join more than 165,000 subscribers and keep yourself informed with latest financial news, insights and expert analysis to help you understand what really matters when it comes to your finances.

Sign up
Latest Videos FromMoneyWeek
MoneyWeek

MoneyWeek is written by a team of experienced and award-winning journalists, plus expert columnists. As well as daily digital news and features, MoneyWeek also publishes a weekly magazine, covering investing and personal finance. From share tips, pensions, gold to practical investment tips - we provide a round-up to help you make money and keep it.